Zurcher Kantonalbank Zurich Cantonalbank Purchases 6,367 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 45.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,305 shares of the company’s stock after acquiring an additional 6,367 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Myriad Genetics were worth $389,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in Myriad Genetics by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,101 shares of the company’s stock valued at $34,000 after purchasing an additional 1,032 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Myriad Genetics by 21.4% in the 4th quarter. Blue Trust Inc. now owns 6,729 shares of the company’s stock valued at $129,000 after acquiring an additional 1,186 shares during the last quarter. Clarus Wealth Advisors purchased a new position in Myriad Genetics in the fourth quarter worth about $204,000. Mutual of America Capital Management LLC increased its stake in Myriad Genetics by 8.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 15,519 shares of the company’s stock worth $297,000 after acquiring an additional 1,167 shares during the last quarter. Finally, Inspire Investing LLC raised its position in Myriad Genetics by 40.8% during the third quarter. Inspire Investing LLC now owns 19,002 shares of the company’s stock valued at $305,000 after purchasing an additional 5,505 shares during the period. 99.02% of the stock is currently owned by institutional investors.

Myriad Genetics Trading Up 1.3 %

MYGN opened at $19.47 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.87 and a current ratio of 2.01. The stock’s 50 day moving average price is $20.79 and its 200-day moving average price is $19.71. Myriad Genetics, Inc. has a one year low of $13.82 and a one year high of $24.21. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -6.08 and a beta of 1.96.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. The company had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative return on equity of 8.03% and a negative net margin of 34.96%. Myriad Genetics’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) EPS. On average, equities analysts forecast that Myriad Genetics, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group boosted their target price on Myriad Genetics from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $23.17.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.